{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-neuropathy","title":"Tesamorelin for Neuropathy: Evidence-Graded Review","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\n\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\n\n## What the evidence actually shows\n\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\n\nPreclinical data: Animal studies indicate growth hormone improves nerve regeneration and functional recovery after injury. These findings form the rationale for the human trial.\n\nHuman safety data from lipodystrophy trials: Tesamorelin reliably lowers visceral adipose tissue and raises IGF-1. Side effects include injection-site reactions, arthralgia, and paresthesia. Some reports list peripheral neuropathy as a possible adverse event.\n\nTier summary: No completed human efficacy trials for neuropathy exist. All neuropathy benefit claims sit at preclinical or mechanistic tier.\n\n## What scientists say\n\nResearchers at Johns Hopkins hypothesize that tesamorelin will speed axonal regeneration via elevated growth hormone. The trial protocol states growth hormone has improved nerve outcomes in animal models. No peer-reviewed conclusions on human neuropathy patients are available yet.\n\n## What people say on Reddit\n\nUsers discuss the ongoing nerve-injury trial. One post notes the study is examining whether tesamorelin helps axons regrow. No personal reports of using tesamorelin specifically for neuropathy symptoms appear in recent threads. General peptide discussions focus on fat loss or side effects such as joint discomfort.\n\n## What people say on X\n\nLimited public posts. Mentions center on the clinical trial announcement or general GH peptide interest. No detailed patient anecdotes on neuropathy resolution.\n\n## What we do not know\n\nWhether tesamorelin improves nerve function, sensation, or pain in humans with neuropathy. Optimal timing after injury. Effects in diabetic or chemotherapy-induced neuropathy. Long-term nerve-specific outcomes. Interaction with other neuropathy treatments.\n\n## Safety and limits\n\nTesamorelin is FDA-approved only for HIV-related visceral fat. It carries risks of fluid retention, joint pain, and glucose changes. Carpal tunnel symptoms and paresthesia have occurred. Active cancer or pituitary disorders are contraindications in approved use. Neuropathy application remains investigational only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current human evidence status for neuropathy application.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Animal studies show growth hormone improves nerve regeneration and functional recovery after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides mechanistic rationale cited in trial design.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human effects on GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights known safety signals relevant to neuropathy readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Active Phase 2 trial protocol details; no results posted.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"fcca5072d19481725c0ae652d53a86c25579cf318fcbf74d974cb88f96062ee1"},{"id":"s2","type":"medical","url":"https://www.centerwatch.com/clinical-trials/listings/NCT03150511/tesamorelin-to-improve-functional-outcomes-after-peripheral-nerve-injury","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"growth hormone has been shown to improve nerve regeneration and functional recovery in animal studies.","summary":"Trial background cites preclinical GH nerve data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"verified","prev":"fcca5072d19481725c0ae652d53a86c25579cf318fcbf74d974cb88f96062ee1","hash":"ef5b229c2a720684fe18a4de499287b7bd43547de5554e169ce2855443b206a0"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","title":"Effects of tesamorelin... in HIV-infected patients with abdominal fat accumulation","quote":"Tesamorelin reduces visceral fat by approximately 18 %","summary":"Pooled Phase 3 data on VAT reduction and IGF-1 increase.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"unverified","prev":"ef5b229c2a720684fe18a4de499287b7bd43547de5554e169ce2855443b206a0","hash":"8f6e93d9e5b2301fc20f368faff9c8746500085e509d7791f366c1ce38dc6b0b"},{"id":"s4","type":"medical","url":"https://www.drugs.com/sfx/tesamorelin-side-effects.html","title":"Tesamorelin Side Effects","quote":"Common (1% to 10%): ... peripheral neuropathy","summary":"Lists neuropathy-related adverse events from approved use.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"http_403","quote_status":"unverified","prev":"8f6e93d9e5b2301fc20f368faff9c8746500085e509d7791f366c1ce38dc6b0b","hash":"2f341cfc8d9e768a393d9aeda50ed4c08f6285f6f8f5595265d9988b3391a996"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:18:00.670Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\n\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\n\n## What the evidence actually shows\n\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\n\nPreclinical data: Animal studies indicate growth hormone improves nerve regeneration and functional recovery after injury. These findings form the rationale for the human trial.\n\nHuman safety data from lipodystrophy trials: Tesamorelin reliably lowers visceral adipose tissue and raises IGF-1. Side effects include injection-site reactions, arthralgia, and paresthesia. Some reports list peripheral neuropathy as a possible adverse event.\n\nTier summary: No completed human efficacy trials for neuropathy exist. All neuropathy benefit claims sit at preclinical or mechanistic tier.\n\n## What scientists say\n\nResearchers at Johns Hopkins hypothesize that tesamorelin will speed axonal regeneration via elevated growth hormone. The trial protocol states growth hormone has improved nerve outcomes in animal models. No peer-reviewed conclusions on human neuropathy patients are available yet.\n\n## What people say on Reddit\n\nUsers discuss the ongoing nerve-injury trial. One post notes the study is examining whether tesamorelin helps axons regrow. No personal reports of using tesamorelin specifically for neuropathy symptoms appear in recent threads. General peptide discussions focus on fat loss or side effects such as joint discomfort.\n\n## What people say on X\n\nLimited public posts. Mentions center on the clinical trial announcement or general GH peptide interest. No detailed patient anecdotes on neuropathy resolution.\n\n## What we do not know\n\nWhether tesamorelin improves nerve function, sensation, or pain in humans with neuropathy. Optimal timing after injury. Effects in diabetic or chemotherapy-induced neuropathy. Long-term nerve-specific outcomes. Interaction with other neuropathy treatments.\n\n## Safety and limits\n\nTesamorelin is FDA-approved only for HIV-related visceral fat. It carries risks of fluid retention, joint pain, and glucose changes. Carpal tunnel symptoms and paresthesia have occurred. Active cancer or pituitary disorders are contraindications in approved use. Neuropathy application remains investigational only.","claims":[{"id":"c1","text":"An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current human evidence status for neuropathy application.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Animal studies show growth hormone improves nerve regeneration and functional recovery after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides mechanistic rationale cited in trial design.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human effects on GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights known safety signals relevant to neuropathy readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"medical","url":"https://www.centerwatch.com/clinical-trials/listings/NCT03150511/tesamorelin-to-improve-functional-outcomes-after-peripheral-nerve-injury","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"growth hormone has been shown to improve nerve regeneration and functional recovery in animal studies.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","title":"Effects of tesamorelin... in HIV-infected patients with abdominal fat accumulation","quote":"Tesamorelin reduces visceral fat by approximately 18 %","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.drugs.com/sfx/tesamorelin-side-effects.html","title":"Tesamorelin Side Effects","quote":"Common (1% to 10%): ... peripheral neuropathy","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":16147,"tokens_out":2701,"cost":0.02693625,"prev_hash":"genesis","hash":"0313958d0df265be83d11e3b6d5261cad09eb7cc209478b9368447f0156eba97"}],"provenance":[{"ts":"2026-06-29T23:18:00.670Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Neuropathy\nSlug: tesamorelin-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptid","response":"{\n  \"slug\": \"tesamorelin-neuropathy\",\n  \"title\": \"Tesamorelin for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\\n\\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\\n\\n## What the evidence actually shows\\n\\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\\n\\nPreclinical data: Animal studies indicate growth hormone improves nerve regener","tokens_in":16147,"tokens_out":2701,"cost":0,"prev":"genesis","hash":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec"},{"ts":"2026-07-17T02:42:24.485Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec","hash":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"}],"energy":{"passes":2,"tokens_in":16147,"tokens_out":2701,"tokens_total":18848,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"},"posted_at":"2026-06-29T21:33:33.843Z","created_at":"2026-06-29T21:33:33.843Z","updated_at":"2026-07-17T02:42:24.485Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-neuropathy","json":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy","bundle":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-neuropathy","json":"/api/articles/tesamorelin-neuropathy","markdown":"/api/articles/tesamorelin-neuropathy/bundle?format=markdown","skill":"/api/articles/tesamorelin-neuropathy/skill","topology":"/api/articles/tesamorelin-neuropathy/topology","versions":"/api/articles/tesamorelin-neuropathy/revisions","invocations":"/api/articles/tesamorelin-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"7edceba6c8f8c500bdde42c7cbec39ee361f75f7cf5367024ee037e8b548f8d0","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-neuropathy","slug":"tesamorelin-neuropathy","title":"Tesamorelin for Neuropathy: Evidence-Graded Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-neuropathy\ndescription: Apply the Tesamorelin for Neuropathy: Evidence-Graded Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Neuropathy: Evidence-Graded Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-neuropathy.\n- Read claims and relationships at /api/articles/tesamorelin-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Neuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Infl\n\n## Representations\n\n- Human: /a/tesamorelin-neuropathy\n- JSON: /api/articles/tesamorelin-neuropathy\n- Relationships: /api/articles/tesamorelin-neuropathy/topology\n- History: /api/articles/tesamorelin-neuropathy/revisions\n"},"json":{"route":"/api/articles/tesamorelin-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-neuropathy/invocations?status=success","failure_events":"/api/articles/tesamorelin-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-neuropathy","title":"Tesamorelin for Neuropathy: Evidence-Graded Review","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\n\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\n\n## What the evidence actually shows\n\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\n\nPreclinical data: Animal studies indicate growth hormone improves nerve regeneration and functional recovery after injury. These findings form the rationale for the human trial.\n\nHuman safety data from lipodystrophy trials: Tesamorelin reliably lowers visceral adipose tissue and raises IGF-1. Side effects include injection-site reactions, arthralgia, and paresthesia. Some reports list peripheral neuropathy as a possible adverse event.\n\nTier summary: No completed human efficacy trials for neuropathy exist. All neuropathy benefit claims sit at preclinical or mechanistic tier.\n\n## What scientists say\n\nResearchers at Johns Hopkins hypothesize that tesamorelin will speed axonal regeneration via elevated growth hormone. The trial protocol states growth hormone has improved nerve outcomes in animal models. No peer-reviewed conclusions on human neuropathy patients are available yet.\n\n## What people say on Reddit\n\nUsers discuss the ongoing nerve-injury trial. One post notes the study is examining whether tesamorelin helps axons regrow. No personal reports of using tesamorelin specifically for neuropathy symptoms appear in recent threads. General peptide discussions focus on fat loss or side effects such as joint discomfort.\n\n## What people say on X\n\nLimited public posts. Mentions center on the clinical trial announcement or general GH peptide interest. No detailed patient anecdotes on neuropathy resolution.\n\n## What we do not know\n\nWhether tesamorelin improves nerve function, sensation, or pain in humans with neuropathy. Optimal timing after injury. Effects in diabetic or chemotherapy-induced neuropathy. Long-term nerve-specific outcomes. Interaction with other neuropathy treatments.\n\n## Safety and limits\n\nTesamorelin is FDA-approved only for HIV-related visceral fat. It carries risks of fluid retention, joint pain, and glucose changes. Carpal tunnel symptoms and paresthesia have occurred. Active cancer or pituitary disorders are contraindications in approved use. Neuropathy application remains investigational only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current human evidence status for neuropathy application.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Animal studies show growth hormone improves nerve regeneration and functional recovery after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides mechanistic rationale cited in trial design.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human effects on GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights known safety signals relevant to neuropathy readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","summary":"Active Phase 2 trial protocol details; no results posted.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"fcca5072d19481725c0ae652d53a86c25579cf318fcbf74d974cb88f96062ee1"},{"id":"s2","type":"medical","url":"https://www.centerwatch.com/clinical-trials/listings/NCT03150511/tesamorelin-to-improve-functional-outcomes-after-peripheral-nerve-injury","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"growth hormone has been shown to improve nerve regeneration and functional recovery in animal studies.","summary":"Trial background cites preclinical GH nerve data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"verified","prev":"fcca5072d19481725c0ae652d53a86c25579cf318fcbf74d974cb88f96062ee1","hash":"ef5b229c2a720684fe18a4de499287b7bd43547de5554e169ce2855443b206a0"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","title":"Effects of tesamorelin... in HIV-infected patients with abdominal fat accumulation","quote":"Tesamorelin reduces visceral fat by approximately 18 %","summary":"Pooled Phase 3 data on VAT reduction and IGF-1 increase.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"ok","quote_status":"unverified","prev":"ef5b229c2a720684fe18a4de499287b7bd43547de5554e169ce2855443b206a0","hash":"8f6e93d9e5b2301fc20f368faff9c8746500085e509d7791f366c1ce38dc6b0b"},{"id":"s4","type":"medical","url":"https://www.drugs.com/sfx/tesamorelin-side-effects.html","title":"Tesamorelin Side Effects","quote":"Common (1% to 10%): ... peripheral neuropathy","summary":"Lists neuropathy-related adverse events from approved use.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:17:59.888Z","link_status":"http_403","quote_status":"unverified","prev":"8f6e93d9e5b2301fc20f368faff9c8746500085e509d7791f366c1ce38dc6b0b","hash":"2f341cfc8d9e768a393d9aeda50ed4c08f6285f6f8f5595265d9988b3391a996"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:18:00.670Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Neuropathy: Evidence-Graded Review","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\n\n## Why Tesamorelin might help you\n\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\n\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\n\n## How these fit together\n\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\n\n## What the evidence actually shows\n\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\n\nPreclinical data: Animal studies indicate growth hormone improves nerve regeneration and functional recovery after injury. These findings form the rationale for the human trial.\n\nHuman safety data from lipodystrophy trials: Tesamorelin reliably lowers visceral adipose tissue and raises IGF-1. Side effects include injection-site reactions, arthralgia, and paresthesia. Some reports list peripheral neuropathy as a possible adverse event.\n\nTier summary: No completed human efficacy trials for neuropathy exist. All neuropathy benefit claims sit at preclinical or mechanistic tier.\n\n## What scientists say\n\nResearchers at Johns Hopkins hypothesize that tesamorelin will speed axonal regeneration via elevated growth hormone. The trial protocol states growth hormone has improved nerve outcomes in animal models. No peer-reviewed conclusions on human neuropathy patients are available yet.\n\n## What people say on Reddit\n\nUsers discuss the ongoing nerve-injury trial. One post notes the study is examining whether tesamorelin helps axons regrow. No personal reports of using tesamorelin specifically for neuropathy symptoms appear in recent threads. General peptide discussions focus on fat loss or side effects such as joint discomfort.\n\n## What people say on X\n\nLimited public posts. Mentions center on the clinical trial announcement or general GH peptide interest. No detailed patient anecdotes on neuropathy resolution.\n\n## What we do not know\n\nWhether tesamorelin improves nerve function, sensation, or pain in humans with neuropathy. Optimal timing after injury. Effects in diabetic or chemotherapy-induced neuropathy. Long-term nerve-specific outcomes. Interaction with other neuropathy treatments.\n\n## Safety and limits\n\nTesamorelin is FDA-approved only for HIV-related visceral fat. It carries risks of fluid retention, joint pain, and glucose changes. Carpal tunnel symptoms and paresthesia have occurred. Active cancer or pituitary disorders are contraindications in approved use. Neuropathy application remains investigational only.","claims":[{"id":"c1","text":"An ongoing Phase 2 RCT (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury with no published results yet.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current human evidence status for neuropathy application.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Animal studies show growth hormone improves nerve regeneration and functional recovery after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides mechanistic rationale cited in trial design.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin reduces visceral fat and increases IGF-1 in multiple human RCTs for HIV lipodystrophy.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human effects on GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Paresthesia and peripheral neuropathy are listed among nervous system adverse events in tesamorelin prescribing information.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Highlights known safety signals relevant to neuropathy readers.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:00.299Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"medical","url":"https://www.centerwatch.com/clinical-trials/listings/NCT03150511/tesamorelin-to-improve-functional-outcomes-after-peripheral-nerve-injury","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"growth hormone has been shown to improve nerve regeneration and functional recovery in animal studies.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20101189/","title":"Effects of tesamorelin... in HIV-infected patients with abdominal fat accumulation","quote":"Tesamorelin reduces visceral fat by approximately 18 %","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.drugs.com/sfx/tesamorelin-side-effects.html","title":"Tesamorelin Side Effects","quote":"Common (1% to 10%): ... peripheral neuropathy","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":16147,"tokens_out":2701,"cost":0.02693625,"prev_hash":"genesis","hash":"0313958d0df265be83d11e3b6d5261cad09eb7cc209478b9368447f0156eba97"}],"provenance":[{"ts":"2026-06-29T23:18:00.670Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Neuropathy\nSlug: tesamorelin-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptid","response":"{\n  \"slug\": \"tesamorelin-neuropathy\",\n  \"title\": \"Tesamorelin for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves degeneration of peripheral nerves. Axons may be damaged or severed after injury or disease. Myelin sheaths can degrade. Schwann cells struggle to support regrowth. Blood flow to nerves may drop. Inflammation can persist. Over time, motor and sensory function decline because repair pathways lag behind ongoing breakdown.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates the growth hormone axis. It raises GH and IGF-1 levels. If your neuropathy involves impaired axonal regeneration or muscle atrophy after nerve injury, this pathway is discussed for potential tissue repair support.\\n\\n1. Therefore for you: If axonal regrowth is a limiting factor, Tesamorelin is studied because GH/IGF-1 signaling has been linked in animal models to faster nerve fiber extension.\\n2. Therefore for you: If muscle wasting follows denervation, the same axis may help preserve or rebuild muscle tissue indirectly.\\n3. Therefore for you: If visceral fat or metabolic stress adds to nerve load, Tesamorelin's documented effect on reducing abdominal fat could ease secondary strain, though this remains separate from direct nerve effects.\\n4. Therefore for you: Tesamorelin targets repair signaling rather than symptom masking.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin addresses the GH axis and visceral fat layer. No sibling peptides are in scope here.\\n\\n## What the evidence actually shows\\n\\nHuman data: One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) is testing tesamorelin after peripheral nerve injury repair. The trial enrolls patients with ulnar nerve lacerations. It measures motor and sensory recovery over one year. As of 2026 the study remains active with no published efficacy results.\\n\\nPreclinical data: Animal studies indicate growth hormone improves nerve regener","tokens_in":16147,"tokens_out":2701,"cost":0,"prev":"genesis","hash":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec"},{"ts":"2026-07-17T02:42:24.485Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"680aa8d693837e73ea0cae398b12c10016159a4c3a64a7ee29dbeeaf117e9eec","hash":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"}],"energy":{"passes":2,"tokens_in":16147,"tokens_out":2701,"tokens_total":18848,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"c254bcb023a5c4bdc278d81300dd2804a8ca78880088ef1dfb608b13732d6cb6"},"posted_at":"2026-06-29T21:33:33.843Z","created_at":"2026-06-29T21:33:33.843Z","updated_at":"2026-07-17T02:42:24.485Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-neuropathy","json":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy","bundle":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-neuropathy","json":"/api/articles/tesamorelin-neuropathy","markdown":"/api/articles/tesamorelin-neuropathy/bundle?format=markdown","skill":"/api/articles/tesamorelin-neuropathy/skill","topology":"/api/articles/tesamorelin-neuropathy/topology","versions":"/api/articles/tesamorelin-neuropathy/revisions","invocations":"/api/articles/tesamorelin-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"7edceba6c8f8c500bdde42c7cbec39ee361f75f7cf5367024ee037e8b548f8d0"}}}